[go: up one dir, main page]

WO2014191056A1 - Combinaison d'agents actifs pour le traitement du vieillissement cutané - Google Patents

Combinaison d'agents actifs pour le traitement du vieillissement cutané Download PDF

Info

Publication number
WO2014191056A1
WO2014191056A1 PCT/EP2013/061325 EP2013061325W WO2014191056A1 WO 2014191056 A1 WO2014191056 A1 WO 2014191056A1 EP 2013061325 W EP2013061325 W EP 2013061325W WO 2014191056 A1 WO2014191056 A1 WO 2014191056A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
collagen
composition
day
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2013/061325
Other languages
English (en)
Inventor
Yann Mahe
Carole BRU
Marjory GRAFFIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutricos Technologies SNC
Original Assignee
Laboratoires Inneov SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Inneov SNC filed Critical Laboratoires Inneov SNC
Priority to BR112015029926A priority Critical patent/BR112015029926A2/pt
Priority to EP13727843.8A priority patent/EP3003264A1/fr
Priority to PCT/EP2013/061325 priority patent/WO2014191056A1/fr
Priority to CN201380078519.5A priority patent/CN105407866A/zh
Publication of WO2014191056A1 publication Critical patent/WO2014191056A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts

Definitions

  • the present invention relates to the field of nutritional and/or cosmetic products which are particularly useful for preventing and/or treating the cutaneous signs of aging, including chronological aging and/or photoaging.
  • the skin In mammals in general, particularly in humans, the skin consists of three compartments, namely a compartment which is in contact with the outside, the epidermis, a deeper compartment which serves as a support for the epidermis, the dermis and the more deeper hypodermis which harbors the skin fat tissue.
  • the dermo-epidermal junction (DEJ) is an important transition zone between the epidermis and the dermis.
  • collagen the most abundant protein in the skin which provides tensile strenght to the skin
  • elastin a protein which forms elastic fibers in the dermis
  • GAGs glycosoaminoglycans
  • PGs proteoglycans
  • the collagen fibers are predominantly responsible for the strength and thickness of the dermis. They are constantly renewed, but this renewal decreases with age, which causes a reduction in the thickness of the dermis.
  • collagen fibers are susceptible to certain enzymes called collagenases which form part of a family of enzymes called metalloproteinases (MMPs).
  • MMPs metalloproteinases
  • the MMP family is composed of several well defined groups based on their similarities in terms of structure and of substrate specificity. Mention may be made, among these groups, of collagenases intended to decompose fibrillar collagens (MMP-1 or interstitial coUagenase, MMP-8 or neutrophil coUagenase, MMP-13 or coUagenase 3, or MMP-18 or coUagenase 4), gelatinases which decompose collagen of type IV or any form of denatured collagen (MMP-2 or gelatinase A (72 kDa), or MMP-9 or gelatinase B (92 kDa), stromelysins (MMP-3 or stromelysin 1, MMP- 10 or stromelysin 2, or MMP-11 or stromelysin 3), the broad spectrum of activity of which applies to proteins of the extracellular matrix, such as glycoproteins (fibronectin, laminin), proteoglycans, and the like, matrilysin
  • age-related dermal macro molecule modifications can be particularly cited collagen modifications such as decrease in collagen content, increase in type III/I collagen ratio, collagen fiber deterioration, and collagen netwok deterioration, elastin modifications such as decrease of elastin content and deterioration of elastic fibers, as well as GAGs and PGs modifications such as decrease of GAGs content, alteration of PGs composition and loss of water-binding capacity.
  • the clinical signs of skin aging involve textural and volume changes such as loss of skin thickness, decrease in skin elasticity and wrinkles onset, and the skin loses firmness, becomes less dense, less elastic, and is less moisturized.
  • the epidermis is relatively colorless not only skin melanocyte at the DEJ but also dermal matrix density, thickness and composition can also contribute to the global color and transparency of the skin.
  • biological alteration of the skin matrix not only contribute to skin plasticity and hydration but can also contribute to some extent to global alteration of skin tone and color, radiance and transparency.
  • the present invention has the aim of satisfying these needs.
  • a subject of the invention is the use of a combination comprising marine, porcine, bovine and/or any origin of collagen and vitamin B3 for having at least one of the beneficial effects on the skin chosen among attenuating the wrinkles, promoting skin plumping or bouncy state of the skin, promoting skin firmness and smoothness, promoting skin hydration and promoting skin radiance.
  • the combination may have two, three or four of the hereabove cited effects simultaneously.
  • the present invention relates to a combination of active agents comprising at least one Silver Ear extract, collagen or a hydrolyzed form thereof, and vitamin B3.
  • the active ingredients are administered in a unique composition, in particular for oral administration.
  • the active ingredients are administered in distinct compositions.
  • the active ingredients may then be administered simultaneously, independently from each other, separately or sequentially and during the same day.
  • cutaneous signs of aging » is understood to mean any modification in the external appearance of the skin due to aging, whether it is chronological and/or photoinduced, such as for example, wrinkles and fine lines, withered skin, soft skin, skin with reduced thickness, dull skin and skin with no brightness, lack of elasticity and/or of tone of the skin, sagged skin, dehydrated skin, but also all the internal modifications of the skin which do not systematically result in a modified external appearance, such as, for example, all the internal damage to the skin, particularly to the collagen fibers, following exposure to ultraviolet radiation, which may have the consequence of reducing the thickness of dermis and mechanical properties.
  • compositions which are orally administrable This has the advantage of acting globally on the entire skin, in its deep layers (dermis, hypodermis), by means of a rapid and relatively non-restrictive mode of administration. Specifically, the metabolites and other active nutriments are in particular distributed within the dermal matrix by means of the bloodstream. Oral administration also has the advantage of a rapid and relatively non- restrictive mode of administration.
  • the oral administration of a combination according to the invention allows improving skin moisturizing (body and face), smoothness, firmness, suppleness and bouncy state on the face.
  • the oral administration of a composition according to the invention allows preventing the degradation of the collagen fibers, to attenuate the wrinkles, to promote skin plumping, skin hydration and consequently skin radiance.
  • the oral administration of a combination according to the invention allows preventing collagen modifications such as decrease in collagen content, increase in type III/I collagen ratio, collagen fiber deterioration, and collagen network deterioration.
  • the oral administration of a combination according to the invention allows preventing elastin modifications such as decrease of elastin content and deterioration of elastic fibers.
  • the oral administration of a combination according to the invention allows preventing GAGs and PGs modifications such as decrease of GAGs content, alteration of PGs composition and loss of water-binding capacity. More particularly, the oral administration of a combination according to the invention allows reducing the thickening of stratum corneum, thinning of epidermis, flattening of DEJ, thinning of dermis, decrease of dermal density, disorganization of dermal network, and decrease of skin hydration.
  • Plumping » means according to the invention to increase the volume and / or thickness of the skin and / or smooth and / or give it a swollen appearance.
  • Skin radiance » is an indication of the healthy condition of the skin. More particularly a luminous, radiant, or even glowing complexion is indicative of skin in good condition.
  • the present invention concerns a nutritional or cosmetic composition for an oral administration comprising at least collagen, preferably marine collagen, or a hydrolyzed form thereof, vitamin B3 and one Silver Ear extract.
  • the present invention relates to a cosmetic use of a combination according to the present invention for preventing and/or treating the cutaneous signs of aging, including chronological aging and/or photoaging, in particular attenuating wrinkles and/or for improving skin moisturizing or hydration, and/or promoting skin plumping and/or for promoting skin radiance.
  • « preventing » means to remove completely or to partially reduce the risk of manifestation of a given phenomenon, that is to say, in the present invention, the cutaneous signs of aging, including chronological aging and/or photoaging.
  • the partial reduction implies that the risk remains, but to a lesser degree than before the implementation of the invention.
  • the present invention relates to a cosmetic process for preventing and/or treating the cutaneous signs of skin aging, including chronological aging and/or photoaging, and more particularly attenuating the wrinkles, and/or for improving skin moisturizing or hydration and/or for promoting skin radiance, and/or for promoting plumping of the skin in an individual in need thereof, comprising at least the oral administration to said individual of a combination according the invention or of a composition according to the invention.
  • the present invention relates to a kit comprising: (i) a first composition for oral administration comprising at least one collagen, preferably marine collagen and vitamin B3, and
  • composition for topical administration comprising at least one moisturizing agent and preferably a Silver Ear extract.
  • Collagen may be of various origins, i.e. porcine collagen, bovine origin, marine origin or any other origin suitable for human administration.
  • collagen is marine collagen.
  • marine collagen also known as fish collagen, it is a material derived from the substance found on fish scales.
  • fish collagen may be produced from the skin of deep water, ocean fish such as cod, haddock, hake, pollock, dab, Japanese bass and tuna.
  • either native or hydrolyzed marine collagen may be used.
  • hydrolyzed marine collagen is used in the combination according to the invention.
  • Hydrolyzed collagen is produced by hydrolysis of the collagen found in the connective tissue of fish.
  • Fish hydrolyzed collagen may have a specific amino acid profile, with particular glycine, proline/hydroxyproline, and glutamic acid contents.
  • a hydrolyzed marine collagen which may be suitable for the present invention is a collagen extract composed of type I hydrolyzed collagen from fish origin, with a process rigorously controlled to obtain a precise degree of hydrolysis and specific aminoacids composition.
  • Said hydrolyzed marine collagen may be produced by hydrolysis of the collagen from fish skin into water soluble peptides.
  • This marine hydrolyzed collagen may for example contain 20% glycine, 20% proline/hydroxyproline and 11% glutamic acid.
  • a hydrolyzed marine collagen which is suitable for the present invention may also be obtained via a biochemical treament in the presence of a protease, may be submitted previously to a mechanical treament so as to obtain it in a form of powder, or may be submitted to a deodorizing treatment via a heating treatment.
  • hydro lyzed fish collagen marketed by the Rousselot company (Angouleme plant, in France) under the names PeptanTMF, PeptanTMF 2000 HD and PeptanTMF 5000 HD may be used in a composition according to the invention.
  • hydro lyzed fish collagen from Rousselot company is made from fish skin coming from tilapia, pangasus, tuna and/or Nile perche and the fishes may come from Costa-Rica, Ecuador, European Union, Ghana, Honduras, Indonesia, Ivory Coast, Malaysia, Thailand, Kenya, Kenya and Vietnam.
  • a further advantage of marine collagen is to stabilize a composition suitable for the invention.
  • the doses of collagen made to achieve the objects of the invention may be adjusted according to the desired effect.
  • it may be provided a dose ranging from 0.1 to 20 g/day, preferably 0.5 to 15 g/day, and preferably from 1 to 9 g/day.
  • Vitamin B3 is a water-soluble compound with the formula C 6 H 5 NO 2 and is also known as nicotinic acid, vitamin PP (for Pellagra Preventive), or niacin. Its amide form is named Nicotinamide (niacinamide). Both are similarly effective and can be converted into each other within the organism.
  • Vitamin B3 is present in most of foods, but exists in particularly high quantities in meat, fish, cereals and mushrooms.
  • Vitamin B3 which may be suitable for the present invention is marketed under the name Niacinamide PC by the DSM company.
  • a composition according to the invention advantageously comprises from 0.0001%) to 1%) by weight, preferably from 0.0005%) to 0.5%> by weight and even more preferentially from 0.001% to 0.1% by weight of vitamin B3 relative to the total weight of the composition.
  • the daily amount of Vitamin B3 is from 0.01 to 30 mg/day, preferably from 0.05 to 25 mg/day, still more preferably from 0.1 to 20 mg/day.
  • SILVER EAR EXTRACT is from 0.01 to 30 mg/day, preferably from 0.05 to 25 mg/day, still more preferably from 0.1 to 20 mg/day.
  • Silver Ear is also called White Jelly Fungus (WJF), white fungus, Tremella fuciformis, snow fungus, silver ear fungus or white jelly mushroom.
  • WJF White Jelly Fungus
  • white fungus Tremella fuciformis
  • snow fungus snow fungus
  • silver ear fungus white jelly mushroom.
  • WJF is a translucent white or even better light yellowish- white jelly fungus that grows on deciduous trees such as oak, maple, poplar, willow in warm and temperate climates worldwide.
  • Tremella fuciformis berk belongs to the Tremellaceae family of the class heterobasidiomycetes.
  • the fungus is known as a nutritious mushroom and an important medicine for people in China.
  • Tremella fuciformis fruiting bodies which are an acknowledged source of non-starch polysaccharides, namely (l->3)-P-D-glucans consisting of a (1->3)- ⁇ - mannan backbone with small xylose- and glucuronic-containing side chains.
  • Silver Ear is a natural source of so-called botanical polysaccharides.
  • a Silver Ear extract which is suitable for the present invention is obtained from the Oryza oil & Fat Chemical Co, ltd. Company (nom commercial White Jelly Fungus Extract).
  • White Jelly Fungus Extract Composed of at least 80% total saccharides and 10-30%) glucuronic acid, White Jelly Fungus Extract is a food item with a supple texture. It sucks water and swells, and gives rise to a large volume of highly viscous transparent solution.
  • a composition according to the invention advantageously comprises from 0.001%) to 5%) by weight, preferably from 0.01% to 5% by weight and even more preferentially from 0.01% to 3% by weight of Tremella fuciformis extract relative to the total weight of the composition.
  • the daily amount of Silver ear is from 1 to 3000 mg/day, preferably from 5 to 2000 mg/day, still more preferably from 10 to 300 mg/day.
  • the selected dose of silver ear extract is of 30mg / 50ml drink.
  • a combination according to the invention may also comprise at least one further active cosmetic agent.
  • such active cosmetic agent can be used to enhance the cosmetic effect as described above.
  • vitamins such as vitamins A, C, D, K, Bl, B2, B3, B5, B6, B8, B9, B12 and E, minerals such as zinc, copper, magnesium, and selenium, essential fatty acids, trace elements, polyphenols, flavonoids, nutritional active anti-aging agents, for example dietary antioxidants, nutrients with anti- free radical enzymes and cofactors endogenous antioxidants, antioxidants such as lipoic acid and coenzyme Q10, superoxide dismutase (SOD), resveratrol, curcuminoids, taurine, carotenoids, xanthophylls, prebiotics, probiotic microorganisms, hyaluronic acid, proteins and amino acids.
  • anti-ageing active agents mention may be made especially of unsaponifiable fractions extracted from fats of plant origin, Aloe vera, and plant or marine oils rich in omega-3 and omega-6 fatty acids (including gammalinolenic acid), photoprotective active agents.
  • a combination of active agents suitable for the invention can be implemented in a cosmetic composition adapted for oral administration.
  • composition according to the invention comprises a physiologically acceptable medium.
  • physiologically acceptable medium is understood to mean a medium devoid of toxicity and compatible with oral use and food safety
  • a combination of active agents according to the invention or a composition according to the invention is orally administered.
  • the oral administration has the advantage of acting globally on the entire skin, in its deep layers (dermis, hypodermis), by means of a rapid and relatively non-restrictive mode of administration.
  • An effective amount of a combination according to the invention or of a composition according to the invention may be administered in a single dose per day or in fractional doses over the day, for example two to three times a day.
  • An oral process may be performed over a time period ranging from one week to several weeks, or even several months, this period moreover possibly being repeated after periods without treatment, for several months or even several years.
  • the oral administration of a composition according to the invention may be performed at a rate, for example, of 2 times a day or more, generally over a prolonged period of at least 4 weeks, or even 4 to 15 weeks, optionally comprising one or more periods of stoppage or being repeated after a period of stoppage.
  • composition means, for example, nutritional, nutraceutical, or cosmeceutical compositions comprising at least one combination according to the invention.
  • food complement or “food supplement” have the same meaning, i.e. a composition for oral administration which is taken separately from the normal diet of a human being, i.e. which cannot be confused with his food, aiming at providing complementary nutriments or active ingredients to him for implementing beneficial effects for his well-being or beauty.
  • health food means food considered to be beneficial to health such as enriched and fortified foods with vitamins and minerals.
  • ingestible support or carrier within the composition comprising said combination according to the invention is preferred.
  • the ingestible support or carrier may be of diverse nature depending on the type of composition under consideration.
  • oral compositions including, food, food supplements and health food are possible.
  • a composition according to the invention may be a food, a food composition or food supplement or may be a health food for human consumption.
  • compositions can be produced by any conventional method known by the man skilled in the art.
  • a composition according to the invention may take the form of a food supplement, and for example a coated tablet, for example sugar-coated tablet, a liquid suspension or solution, a gel, a hydrogel, an emulsion, an oral solution, a flavored drink, tablet to swallow or chew, a capsule, especially a soft or hard capsule, a phial, granules or powder to be dissolved or a syrup.
  • a coated tablet for example sugar-coated tablet, a liquid suspension or solution, a gel, a hydrogel, an emulsion, an oral solution, a flavored drink, tablet to swallow or chew, a capsule, especially a soft or hard capsule, a phial, granules or powder to be dissolved or a syrup.
  • the oral compositions may be either in anhydrous or aqueous form.
  • a combination of active agents according to the invention may take the form of compacted or non compacted powders.
  • the powders may be diluted in water.
  • a composition according to the invention administered orally may be formulated in the form of a food which may take the following form: compact or loose powders, beverages (refreshing drinks, flavored drink, lactobaciUus beverage, etc.), milk or fermented milks or fermented soymilk.
  • milk for example, milk, fermented milk, fermented products made from milk, food supplements in dry form and food supplements in liquid form may be suitable.
  • the active agents according to the invention may moreover be formulated with the usual excipients and components for such oral compositions or food supplements, i.e. in particular fatty and/or aqueous components, humectants, thickeners, preservatives, texturing agents, flavour enhancers and/or coating agents, antioxidants, preservatives and dyes that are customary in the food sector.
  • excipients and components for such oral compositions or food supplements i.e. in particular fatty and/or aqueous components, humectants, thickeners, preservatives, texturing agents, flavour enhancers and/or coating agents, antioxidants, preservatives and dyes that are customary in the food sector.
  • the formulating agents and excipients for oral compositions, and in particular for food supplements, are known in this field and will not be the subject of a detailed description herein.
  • a combination or a composition according to the invention, administered orally is formulated in the form of a beverage, a drink, a stick-gel, or a powder to be diluted in a liquid such as water or fruit juice, vegetable juice, and more preferably in the form of a drink.
  • any of the additional active agents as previously described may be added to a composition in accordance with the invention.
  • the support or carrier may be of various natures, depending on the type of composition under consideration.
  • a combination according to the invention or a composition according to the invention is useful for preventing and/or treating the cutaneous signs of aging, including chronological aging and/or photoaging, for skin regeneration and repair, for improving the quality of the skin, for dermal matrix skin protection, for reducing or preventing wrinkles and/or fine lines, withered skin, slackened skin, lack of skin elasticity and/or tonicity, thinning of the dermis, degradation of collagen fibres, flaccid skin, thinned skin and any internal degradation of the skin, for improving and/or reducing the microrelief of the skin and/or for maintaining and/or improving the barrier function of the skin, for maintaining and/or reinforcing the epidermis and/or the dermis, or for maintaining the integrity and/or thickness of the various layers of the skin, for making the skin smooth, for improving the mechanical properties of the skin and/or for promoting skin repair, for improving the density and/or firmness of the skin, and/or for increasing the synthesis of collagens, for making the skin
  • composition according to the present invention or kit according to the present invention is useful for attenuating wrinkles and/or promoting skin plumping or bouncy state of the skin and/or promoting skin firmness and skin smoothness and/or promoting hydration and/or promoting skin radiance.
  • the wrinkles are in particular those which lay out radially around the mouth and/or of the eyes, in particular the wrinkles of the crow's feet, the wrinkles under the eye and/or located at the level of the face, in particular the wrinkle known as of glabelar lines, located at the level of gabelle, in space inter-sourcillier, and/or horizontally laid out on the face, the wrinkles of the furrow nasogenien, and the ptose of the bottom of the face.
  • compositions (i) and (ii) comprised in a kit in accordance with the invention may be administered, independently from each other, simultaneously, separately or sequentially.
  • Any moisturizing agent may be present in the composition (ii) and preferably a Silver Ear extract, and any of the additional active agents as previously described may also be added to a kit in accordance with the invention.
  • the topical composition (ii) can advantageously be formulated in any dosage form suitable for the care of the skin and mucous membranes and may be in the form of ointments, creams, milks, ointments, powders, impregnated pads, solutions, gels, sprays, lotions or suspensions. It can also be in the form of microspheres or nanospheres or of lipid or polymeric vesicles or of polymeric patches and hydrogels for controlled release.
  • This composition for topical administration can be either in anhydrous form or in aqueous form as an indication dermocosmetics.
  • a composition for administration by the topical route may be an aqueous, hydro alcoholic or oily solution or dispersion of the lotion or serum type, emulsions of liquid or semi-liquid milk type, obtained by dispersion of a phase fat in an aqueous phase (O/W) or conversely (W/O), a suspension or an emulsion, a soft, semi-solid or solid, of the cream or gel-like aqueous or anhydrous, a multiple emulsion (E/O/W or 0/W/O), a microemulsion, a nanoemulsion, a microcapsule preparation, a preparation of microparticles, or a vesicular dispersion of ionic and / or nonionic surfactant, or a wax / aqueous phase.
  • O/W aqueous phase
  • W/O conversely
  • a suspension or an emulsion a soft, semi-solid or solid, of the cream or gel-like aque
  • a topical composition may be in the form of a solution, a cream, a gel, an emulsion, foam or an aerosol composition containing a propellant.
  • a topical composition may also be in the form of a transdermal system to release active or passive / active in (s) by transdermal route e.g. patch type or gel patch type (hydrogel).
  • compositions are prepared according to conventional methods.
  • the present invention relates to a cosmetic process for preventing and/or treating the cutaneous signs of skin aging, including chronological aging and/or photoaging, and more particularly attenuating wrinkles, and/or for improving skin moisturizing or hydration and/or for promoting skin radiance, and/or promoting skin plumping of the skin in an individual in need thereof, comprising at least the oral administration to said individual of a combination or of a composition according to the invention.
  • a process according to the invention may be implemented on a daily basis for example, due for example to a single dose per day or twice daily administration, for example, once in the morning and once in the evening, or three times a day, including meals.
  • a cosmetic process according to the invention can be implemented, for example by daily administration of a composition formulated for example as capsules, coated tablets, flavored drink, emulsions, tablets, capsules or phials, in adequate amount and number, according to their formulation.
  • An effective amount of a combination according to the invention may be administered in a single daily dose or in divided doses throughout the day, such as two to three times a day doses.
  • a process according to the invention may advantageously comprise a single administration.
  • a cosmetic process can be implemented over a period of time ranging from one week to several weeks or months, this period may also be repeated after periods of non-treatment for several months or even several years.
  • the administration of a combination of active agents according to the invention can be carried out, for example, two times a day, usually over a prolonged period of at least 4 weeks or even 4 to 15 weeks, optionally comprising one or more periods of interruption or being repeated after a period of interruption.
  • the ingredients are mixed, before being formulated, in the order and under conditions that can be readily determined by those skilled in the art.
  • compositions of the invention are adjusted by those skilled in the art in such a way as not to substantially affect the properties required for the compositions of the invention.
  • Example 1 anti-aging drink
  • This composition is available in the form of a drink of 50ml.
  • This drink is to be drunk once to three times per day during from seven days to three months.
  • Example 2 drink
  • Combination of white fungus extract (Silver ear), extract of fish collagen and Vitamin B3 allows to limit the activation of MMPl and MMP9 by UV and more particularly allows to improve skin radiance and skin hydration.
  • This drink is to be drunk from 15 days to 1 month before, then during and after sun exposure.
  • Example 3 stick (water dispersible powder)
  • This stick is diluted in a glass containing water or fruit juice and is absorbed two times a day.
  • This stick-gel is useful for improving the quality of the skin, and more particularly for reducing wrinkles and fine lines, for improving skin elasticity and tonicity.
  • Example 4 clinical evaluation on the combination marine collagen and vitamin
  • a clinical evaluation was performed on 105 volunteers (30-45 years old Asiatic women with a BMI ranging from 19 to 26 kg/m 2 ) to assess the effects of a combination of collagen and vitamine B3 under the form of a flavored beverage on skin qualities.
  • the average age was 37.20 ⁇ 3.5
  • the average BMI was 22.10 ⁇ 1.8
  • Marine fish collagen 3 333.33 mg/bottle
  • ITT population means Intent To Treat Population.
  • the dermatologist had to score from 1 to 10, "1" being the best score and "10" the worse score. An improvement is represented by a decrease of the mean score.
  • a result was considered as clinically relevant if the evolution was statistically significantly different from baseline (p ⁇ 0.05) and if the evolution was of 1 score at least.
  • the number of "responders” was calculated for each time (a "responders” is defined as a subject with an improvement of 1 score at least between 2 times).
  • the subject had to score from 1 to 10, "1" being the best score and "10" the worse score.
  • An improvement is represented by a decrease of the mean score.
  • a “responders” was calculated for each time (a “responders” is defined as a subject with an improvement of 1 score at least between 2 times).
  • the percentage of satisfied volunteers increased over the supplementation period. After 3 months of supplementation more than 92% of the volunteers were satisfied for all efficacy criteria.
  • the percentage of "satisfied subjects” corresponds to the addition of the 3 possible answers related to a “satisfaction” ("definitely agree”, “really agree”, “rather agree”).
  • Rz max parameter corresponds to the difference between the "higher” and the “lower” points, i.e. between extremes. A decrease of this height means the skin is smoother and the wrinkles less deep.
  • Ra parameter measures the mean roughness (arithmetic) on the overall photograph. Lower is Ra value, smoother is the surface of the skin.
  • Rq parameter measures the quadratic roughness on the overall photograph. It gives more importance to extreme points. Lower is Rq value, smoother is the surface of the skin.
  • Skewness parameter measures the surface asymmetry.
  • a skewness value 0 means skin surface is perfectly symmetrical.
  • An increase of skewness parameter is related to a decrease of the plateaus, i.e. a younger skin surface.
  • the first action of a supplementation on the relief will be to decrease the maximal superior and inferior points then to reduce the whole set of extreme points then to decrease all the points.
  • an oral supplementation acts from the depth of the skin so it is usually observed a first action on the deeper furrows. The action on the picks is more characteristic of topical products.
  • Figure 1 represents macrophotographs (subject n°015), which are an example of illustration of what happens in depth. They only are examples and do not represent the effects on the whole population of the study. This effect is not visible by human eye.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation d'une combinaison comprenant du collagène, de préférence du collagène marin ou une forme hydrolysée de celui-ci et de la vitamine B3 pour avoir sur la peau au moins l'un des effets bénéfiques suivants : atténuation des rides, promotion du repulpage de la peau ou de l'élasticité de la peau, promotion de la fermeté et de la douceur de la peau, promotion de l'hydratation de la peau et promotion de l'éclat de la peau. La présente invention concerne en outre une combinaison d'agents actifs comprenant au moins du collagène ou une forme hydrolysée de celui-ci, de la vitamine B3 et un extrait de Tremella ainsi qu'un procédé cosmétique associé.
PCT/EP2013/061325 2013-05-31 2013-05-31 Combinaison d'agents actifs pour le traitement du vieillissement cutané Ceased WO2014191056A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BR112015029926A BR112015029926A2 (pt) 2013-05-31 2013-05-31 combinação de agentes ativos para o tratamento de envelhecimento da pele
EP13727843.8A EP3003264A1 (fr) 2013-05-31 2013-05-31 Combinaison d'agents actifs pour le traitement du vieillissement cutané
PCT/EP2013/061325 WO2014191056A1 (fr) 2013-05-31 2013-05-31 Combinaison d'agents actifs pour le traitement du vieillissement cutané
CN201380078519.5A CN105407866A (zh) 2013-05-31 2013-05-31 用于处理皮肤老化的活性剂的组合

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/061325 WO2014191056A1 (fr) 2013-05-31 2013-05-31 Combinaison d'agents actifs pour le traitement du vieillissement cutané

Publications (1)

Publication Number Publication Date
WO2014191056A1 true WO2014191056A1 (fr) 2014-12-04

Family

ID=48579037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/061325 Ceased WO2014191056A1 (fr) 2013-05-31 2013-05-31 Combinaison d'agents actifs pour le traitement du vieillissement cutané

Country Status (4)

Country Link
EP (1) EP3003264A1 (fr)
CN (1) CN105407866A (fr)
BR (1) BR112015029926A2 (fr)
WO (1) WO2014191056A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016207642A1 (fr) * 2015-06-26 2016-12-29 Colltec Limited Formulation
CN107184412A (zh) * 2017-04-14 2017-09-22 绍兴金石生物工程有限公司 一种保湿修复液的制作方法
CN108835629A (zh) * 2018-07-27 2018-11-20 王广生 一种营养补充剂
CN110507582A (zh) * 2019-09-23 2019-11-29 中国科学院烟台海岸带研究所 一种含复合植物提取物的抗衰修复组合物及其制备方法和应用
CN113826885A (zh) * 2021-09-03 2021-12-24 江南大学 高产sod青梅酵素的制备方法及应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107400160B (zh) * 2017-08-07 2020-07-03 温州千瑞生物科技有限公司 抗松弛、紧致的肽以及包含其的化妆品
CN109966555A (zh) * 2019-05-06 2019-07-05 常州立新医疗美容诊所有限公司 一种弹性细胞塑颜用面部填充剂组合物凝胶及其制备方法
CN114762698A (zh) * 2021-06-16 2022-07-19 艾琳娜医疗管理(南京)有限公司 女性面部刺激胶原修复营养液及其设备方法
CN116268382A (zh) * 2023-05-20 2023-06-23 广东泰升药业有限公司 一种银耳陈皮花胶及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2592790A1 (fr) * 1986-01-16 1987-07-17 Villano Guy Preparation cosmetique a action regeneratrice et antirides
JP2006131557A (ja) * 2004-11-05 2006-05-25 Nippon Menaade Keshohin Kk 皮膚外用剤
CN101731589A (zh) * 2008-11-06 2010-06-16 董四清 皮骨冻工艺制作技术
US20120058140A1 (en) * 2010-09-02 2012-03-08 Bath & Body Works Brand Management, Inc. Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities
WO2012120290A2 (fr) * 2011-03-04 2012-09-13 Sana Pharma As Formulations cosmétiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102836093B (zh) * 2012-09-26 2013-06-12 关节动力安达（天津）生物科技有限公司 一种含有i型胶原蛋白的面霜

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2592790A1 (fr) * 1986-01-16 1987-07-17 Villano Guy Preparation cosmetique a action regeneratrice et antirides
JP2006131557A (ja) * 2004-11-05 2006-05-25 Nippon Menaade Keshohin Kk 皮膚外用剤
CN101731589A (zh) * 2008-11-06 2010-06-16 董四清 皮骨冻工艺制作技术
US20120058140A1 (en) * 2010-09-02 2012-03-08 Bath & Body Works Brand Management, Inc. Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities
WO2012120290A2 (fr) * 2011-03-04 2012-09-13 Sana Pharma As Formulations cosmétiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 201051, Derwent World Patents Index; AN 2010-J07315, XP002719432 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016207642A1 (fr) * 2015-06-26 2016-12-29 Colltec Limited Formulation
CN107184412A (zh) * 2017-04-14 2017-09-22 绍兴金石生物工程有限公司 一种保湿修复液的制作方法
CN108835629A (zh) * 2018-07-27 2018-11-20 王广生 一种营养补充剂
CN110507582A (zh) * 2019-09-23 2019-11-29 中国科学院烟台海岸带研究所 一种含复合植物提取物的抗衰修复组合物及其制备方法和应用
CN113826885A (zh) * 2021-09-03 2021-12-24 江南大学 高产sod青梅酵素的制备方法及应用
CN113826885B (zh) * 2021-09-03 2022-04-29 江南大学 高产sod青梅酵素的制备方法及应用

Also Published As

Publication number Publication date
EP3003264A1 (fr) 2016-04-13
CN105407866A (zh) 2016-03-16
BR112015029926A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
WO2014191056A1 (fr) Combinaison d'agents actifs pour le traitement du vieillissement cutané
CA2745774C (fr) Association de lycopene, polyphenol et vitamines pour le soin des matieres keratiniques
WO2015083630A1 (fr) Composition contenant un peptide de collagène, un peptide d'élastine et un protéoglycane
CN102973486B (zh) 一种滋养驻颜洗面奶及其制备方法
CN101693108A (zh) 用于皮肤美容的口服营养组合物
CN101828661A (zh) 一种用于改善皮肤水分、除皱的保健食品
AU2012344135B2 (en) Collagen hydrolysate and use thereof
CN113521258A (zh) 一种改善衰老的组织注射液
CN113768853A (zh) 一种美白淡斑组合物及其制备方法和应用
CN102973937B (zh) 具有皮肤美容功效的组合物及包含该组合物的口服化妆品
KR20080090808A (ko) 피부미용을 위한 건강보조식품의 조성물
CN109528536A (zh) 一种含有胆碱鞣花酸盐的护肤品及其制备方法
CN106361667B (zh) 蛇油膏
US20180117070A1 (en) Oral care composition
JP2001226286A (ja) 肌細胞活性物質
JP2006219432A (ja) 肌荒れ防止作用を有する組成物および化粧料、飲料
JP2012067082A (ja) 経口組成物
US20170231886A1 (en) Method and composition for improving skin health and reducing visible signs of skin aging
FR3004347A1 (fr) Composition cosmetique comprenant une huile essentielle de sauge et son utilisation
CN115336687A (zh) 一种二氢槲皮素透明质酸钠液
CN109248125A (zh) 一种含有蜂王浆提取物的天然滋润抗衰面膜
Andres et al. Supplementation with Ovoderm® Reduces the Clinical Signs of Skin Aging. A Double-Blind, Placebo-Controlled Study
KR101944261B1 (ko) 닭발 콜라겐을 함유하는 주름개선 화장료 조성물의 제조방법
CN116491615B (zh) 美藤果油胶原蛋白肽饮料组合物及其制备方法
KR102484277B1 (ko) 피부 미용 개선용 원료 조성물의 제조방법

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201380078519.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13727843

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 122019025504

Country of ref document: BR

Ref document number: 2013727843

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015029926

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015029926

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20151130